Hidrocloruro De Efedrina Altan (Ephedrine Hydrochloride)

Hidrocloruro De Efedrina Altan is indicated for several acute medical situations where stimulation of the sympathetic nervous system is required.

• Management of hypotension, especially during anesthesia or shock.
• Relief of bronchospasm associated with asthma or chronic obstructive pulmonary disease.
• Temporary reduction of nasal congestion caused by upper respiratory infections.
• Adjunctive therapy to increase blood pressure in certain surgical procedures.
• Central nervous system stimulant use under strict monitoring for selected diagnostic tests.

• Ephedrine hydrochloride acts as an indirect sympathomimetic amine. It enters adrenergic nerve terminals and displaces norepinephrine from storage vesicles, increasing its extracellular concentration. In addition, the molecule directly stimulates α‑ and β‑adrenergic receptors, producing vasoconstriction, increased cardiac output, and bronchodilation. The combined indirect and direct actions raise systemic vascular resistance and airway smooth‑muscle relaxation, accounting for its vasopressor and bronchodilator overall clinically effects.

Adverse reactions to ephedrine hydrochloride may vary in frequency and severity.

Common

• Increased heart rate (tachycardia)
• Elevated blood pressure
• Nervousness or restlessness
• Tremor
• Headache
• Insomnia

Serious

• Cardiac arrhythmias
• Severe hypertension
• Myocardial ischemia
• Cerebral hemorrhage
• Allergic reactions such as rash or anaphylaxis

When prescribing Hidrocloruro De Efedrina Altan, clinicians should consider several precautionary measures to minimize risk.

• Assess cardiovascular status before use, especially in patients with coronary artery disease.
• Avoid in uncontrolled hypertension or hyperthyroidism.
• Use cautiously in pregnant or breastfeeding individuals; data are limited.
• Monitor for signs of central nervous system stimulation, such as agitation or seizures.
• Adjust dose or discontinue if severe tachyarrhythmias develop.
• Consider renal or hepatic impairment may affect drug elimination.
• Ensure appropriate intravenous administration techniques to prevent extravasation.

Ephedrine hydrochloride can interact with other medications, altering its efficacy or safety profile.

Avoid

• Monoamine oxidase inhibitors (MAOIs) – risk of hypertensive crisis.
• β‑blockers – may blunt cardiovascular response.
• Tricyclic antidepressants – increased sympathomimetic effects.

Use with caution

• Other sympathomimetic agents (e.g., pseudoephedrine) – additive pressor effects.
• Diuretics – may exacerbate electrolyte disturbances.
• Anticoagulants – potential for increased blood pressure affecting bleeding risk.